Evidence map›Paper›PMID 25114589›Full record

ArticleBreast cancer (Dove Medical Press)2014

Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer.

Johannes Wohlrab, Nikola Bangemann, Anke Kleine-Tebbe, Marc Thill, Sherko Kümmel, Eva-Maria Grischke, Rainer Richter, Sophie Seite, Diana Lüftner

Open access · goldAbstract read
In one paragraph

Article in Breast cancer (Dove Medical Press), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Cosmetic considerations after breast cancer treatment.Archives of dermatological research · 2024
    Review
  4. Review
  5. The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Review
  6. [Therapeutic peculiarities in diseases of the nipple skin].Dermatologie (Heidelberg, Germany) · 2022
    Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 3 countries.

Johannes WohlrabMartin Luther University Halle-Wittenberg, Department of Dermatology and Venereology, Halle (Saale), Germany.
Nikola BangemannInterdisciplinary Breast Centre, University Hospital Charité Berlin, Campus Benjamin Franklin, Berlin, Germany.
Anke Kleine-TebbeBreast Centre DRK Hospital, Berlin, Germany.
Marc ThillBreast Centre University of Lübeck, Department of Gynaecology and Obstetrics, Lübeck, Germany ; Department of Gynaecology and Obstetrics, Agaplesion Markus Hospital, Frankfurt am Main, Germany.
Sherko KümmelBreast Centre and Clinic of Senology, Hospital Essen-Mitte, Essen, Germany.
Eva-Maria GrischkeBreast Centre University of Tübingen, Department of Gynaecology, Tübingen, Germany.
Rainer RichterL'Oréal, Deutschland GmbH, Düsseldorf, Germany.
Sophie SeiteLa Roche-Posay, Dermatological Laboratories, Asnières, France.
Diana LüftnerUniversity Hospital Charité Berlin, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumour Immunology, Berlin, Germany.
Charité - Universitätsmedizin Berlin · DEADK Hospital · MVAgaplesion Markus Hospital · DEKliniken Essen-Mitte · DEMartin Luther University Halle-Wittenberg · DERoche (France) · FRUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeChemotherapy with anthracyclines, taxanes, or alkylating agents often causes cutaneous side effects. Nonspecific inhibition of the proliferative activity of keratinocytes has antidifferentiation effects that lead to defects in the barrier function and, thus, to dry, itchy, and irritable skin. These cutaneous symptoms reduce the quality of life of the patients considerably. Conditioning with topical application of niacinamide uses the cytoprotective and barrier stabilizing effect of vitamin B3. PATIENTS AND

methodsA multicenter randomized crossover study investigated the influence of the test preparation on the quality of life compared to standard care for 73 patients with breast cancer undergoing adjuvant or neoadjuvant cytostatic therapy. Primary target parameter was the Dermatology Life Quality Index with its respective subscales after 6 weeks of a twice-daily application of the respective preparations. Additionally, specific symptoms such as pruritus, dryness, and irritability have been assessed using visual analog scales.

resultsRegarding the total score of the Dermatology Life Quality Index, no relevant differences could be observed. However, the results for the "symptoms and feelings" subscale show a significant advantage in favor of the test preparation. Significant superiority of the test preparation could also be observed in the secondary target parameters, the visual analog scales (P<0.05).

conclusionThe results show for the first time a significant superiority of prophylactic application of niacinamide for maintaining quality of life while undergoing cytostatic treatment.

Indexed as

anthracyclinechemotherapyniacinamidesupportive therapytaxane

Identifiers

PMID25114589
PMCPMC4126578
OpenAlexW2071669127

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.